FDA Grants Accelerated Approval to Enfortumab Vedotin for the Treatment of Urothelial…

Enfortumab vedotin-ejfv has been approved by the FDA for treatment of patients with locally advanced or metastatic urothelial cancers who had prior treatment with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy regimen, according to a press release from the FDA.

Read the full article here

Related Articles